Compare Stocks

→ The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (From Smallcaps Daily) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCTX BriaCell Therapeutics	$1.53 -6.1%	$2.50	$1.46 ▼ $7.59	$24.45M	1.14	82,467 shs	80,323 shs
OCUP Ocuphire Pharma	$1.71 -1.2%	$1.87	$1.50 ▼ $5.00	$44.33M	0.39	214,098 shs	23,337 shs
UNCY Unicycive Therapeutics	$1.06 -2.3%	$1.27	$0.47 ▼ $1.82	$39.68M	2.72	353,919 shs	41,169 shs
XLO Xilio Therapeutics	$1.08 -3.6%	$1.05	$0.49 ▼ $3.25	$39.86M	-0.13	902,133 shs	82,896 shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCTX BriaCell Therapeutics	-20.38%	-25.00%	-27.59%	-47.99%	-73.38%
OCUP Ocuphire Pharma	+1.76%	-5.46%	-1.70%	-34.72%	-64.62%
UNCY Unicycive Therapeutics	-0.92%	-4.42%	-5.26%	-17.56%	-21.17%
XLO Xilio Therapeutics	+2.75%	-7.44%	-11.11%	+90.67%	-64.33%

Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (Ad)

The AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016.

Get the full story here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCTX BriaCell Therapeutics	2.1241 of 5 stars	3.5	3.0	2.9	1.7	0.0
OCUP Ocuphire Pharma	2.7948 of 5 stars	3.6	4.0	1.0	1.7	1.3
UNCY Unicycive Therapeutics	2.4001 of 5 stars	3.5	3.0	1.6	2.5	0.6
XLO Xilio Therapeutics	0.5541 of 5 stars	0.0	2.0	1.5	2.5	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCTX BriaCell Therapeutics	3.00	Buy	$18.00	1,076.47% Upside
OCUP Ocuphire Pharma	3.20	Buy	$18.75	996.49% Upside
UNCY Unicycive Therapeutics	3.00	Buy	$5.30	402.37% Upside
XLO Xilio Therapeutics	3.00	Buy	N/A	N/A

Current Analyst Ratings

Latest UNCY, BCTX, XLO, and OCUP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2024	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.50
5/13/2024	OCUP Ocuphire Pharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2024	OCUP Ocuphire Pharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $18.00
5/13/2024	OCUP Ocuphire Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
4/15/2024	UNCY Unicycive Therapeutics	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Speculative Buy ➝ Speculative Buy	$3.00
4/4/2024	UNCY Unicycive Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$9.00
4/1/2024	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.50
3/20/2024	OCUP Ocuphire Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $20.00
3/14/2024	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.50
3/5/2024	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.50

(Data available from 5/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCTX BriaCell Therapeutics	N/A	N/A	N/A	N/A	($0.24) per share	N/A
OCUP Ocuphire Pharma	$19.01M	2.33	N/A	N/A	$1.78 per share	0.96
UNCY Unicycive Therapeutics	$680K	58.35	N/A	N/A	($0.11) per share	-9.59
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	$1.34 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCTX BriaCell Therapeutics	-$20.30M	-$1.68	N/A	N/A	N/A	N/A	N/A	-57.48%	6/12/2024 (Estimated)
OCUP Ocuphire Pharma	-$9.99M	-$0.49	N/A	N/A	N/A	-59.44%	-24.57%	-22.22%	8/9/2024 (Estimated)
UNCY Unicycive Therapeutics	-$30.54M	-$1.19	N/A	N/A	N/A	N/A	N/A	-133.36%	8/12/2024 (Estimated)
XLO Xilio Therapeutics	-$76.40M	-$2.78	N/A	N/A	N/A	N/A	-126.55%	-89.20%	8/12/2024 (Estimated)

Latest UNCY, BCTX, XLO, and OCUP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/1/2024	Q4 2023	XLO Xilio Therapeutics	N/A	-$0.64	-$0.64	-$0.64	N/A	N/A
3/28/2024	Q4 2023	UNCY Unicycive Therapeutics	-$0.18	-$0.16	+$0.02	-$0.16	N/A	N/A
3/18/2024	Q2 2024	BCTX BriaCell Therapeutics	-$0.20	-$0.71	-$0.51	-$0.71	N/A	N/A
3/8/2024	Q4 2023	OCUP Ocuphire Pharma	-$0.07	-$0.21	-$0.14	-$0.21	$3.47 million	$1.69 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCTX BriaCell Therapeutics	N/A	N/A	N/A	N/A	N/A
OCUP Ocuphire Pharma	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCTX BriaCell Therapeutics	N/A	2.99	2.99
OCUP Ocuphire Pharma	N/A	8.96	13.35
UNCY Unicycive Therapeutics	N/A	0.76	0.76
XLO Xilio Therapeutics	N/A	3.02	3.02

Ownership

Institutional Ownership

Company	Institutional Ownership
BCTX BriaCell Therapeutics	15.42%
OCUP Ocuphire Pharma	14.97%
UNCY Unicycive Therapeutics	40.42%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
BCTX BriaCell Therapeutics	21.77%
OCUP Ocuphire Pharma	8.70%
UNCY Unicycive Therapeutics	42.00%
XLO Xilio Therapeutics	4.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BCTX BriaCell Therapeutics	16	15.98 million	12.50 million	Optionable
OCUP Ocuphire Pharma	14	25.92 million	23.38 million	Optionable
UNCY Unicycive Therapeutics	12	37.61 million	21.81 million	Not Optionable
XLO Xilio Therapeutics	73	36.91 million	35.21 million	Not Optionable

UNCY, BCTX, XLO, and OCUP Headlines

Recent News About These Companies

May 14 at 3:13 PM | investorplace.com

XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024

May 14 at 7:30 AM | globenewswire.com

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

May 13 at 2:25 AM | americanbankingnews.com

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

April 17, 2024 | msn.com

Xilio Therapeutics (XLO) Price Target Increased by 17.86% to 5.61

April 16, 2024 | zacks.com

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why

April 12, 2024 | stocknews.com

3 Biotech Stocks to Invest In Right Now for Long-Term Gains

April 4, 2024 | insidertrades.com

Gilead Sciences, Inc. Buys 485,250 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) Stock

April 2, 2024 | investorplace.com

XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023

April 1, 2024 | globenewswire.com

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

March 31, 2024 | pennystocks.com

Sizing Your Penny Stocks Position, 3 Tips

March 29, 2024 | precisionmedicineonline.com

Gilead Sciences Licenses Xilio Therapeutics' IL-12 Molecule XTX301

March 29, 2024 | marketwatch.com

Xilio Shares Take Flight Premarket After Gilead Deal

March 28, 2024 | investorplace.com

Why Is Xilio Therapeutics (XLO) Stock up 168% Today?

March 28, 2024 | marketwatch.com

Xilio Therapeutics Plans Private Placement, Job Cuts

March 28, 2024 | markets.businessinsider.com

Xilio Prices Private Placement Of $11.3 Mln Of Shares, Updates XTX202 Trial; To Axe 21% Of Jobs

March 28, 2024 | globenewswire.com

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

February 28, 2024 | globenewswire.com

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

February 27, 2024 | morningstar.com

Xilio Therapeutics Inc XLO

January 31, 2024 | finance.yahoo.com

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

January 8, 2024 | finance.yahoo.com

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BriaCell Therapeutics

NASDAQ:BCTX

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Ocuphire Pharma

NASDAQ:OCUP

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Unicycive Therapeutics

NASDAQ:UNCY

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Xilio Therapeutics

NASDAQ:XLO

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial